Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 1997

View Archived Issues

Merck & Co. reports NOS inhibitors

5-HT2C/2A receptor antagonists from Egis

RXR-selective compounds disclosed by Allergan

Agents for psoriasis and cancers from Roche

NicOx reveals antiinflammatory/antithrombotic compounds with low toxicity

Merck & Co. discloses muscarinic antagonists for myopia

Agents for glaucoma revealed by Merck & Co.

Novel immunosuppressants prepared by Merck & Co.

Combination therapy approved by FDA for H. pylori eradication

Antifungal activity of nikkomycin Z alone and in combination with azoles

FDA advisory committee to review rituximab BLA

Crystal structure of BPI described by Xoma/UCLA

BioQuest to acquire Immune Complex Corporation

ERT reported to protect against AD

Axcan to distribute Ursofalk in Canada

Preclinical results reported by Lilly and Synaptic for potent and selective 5-HT1F agonist

Trega Biosciences and Northwest Neurologic sign drug discovery agreement

New antifungals under development

New polyene from SPA compared to amphotericin B

Hi-Tech Pharmacal obtains license to huperzine

New sordarin derivatives from Glaxo Wellcome

Agouron's IND for anticancer agent approved

Labopharm and Sepracor to develop new dosage forms of levalbuterol

Lilly and Serenics to codevelop psychopharmacologic and cardiovascular drugs

Triazole antifungals under development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026